Table of Content



Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Disease type
1.2.2. Therapeutics class
1.2.3. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Disease type outlook
2.2.2. Therapeutics class outlook
2.3. Competitive Insights
Chapter 3. China Lung Cancer Therapeutics Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing incidence of lung cancer
3.2.1.2. Aging population
3.2.1.3. Advancements in medical diagnostic equipment
3.2.2. Market Restraint Analysis
3.2.2.1. High costs of advanced immunotherapies and targeted therapies
3.3. China Lung Cancer Therapeutics Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Bargaining power of suppliers
3.3.1.2. Bargaining power of buyers
3.3.1.3. Threat of substitutes
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Economic landscape
3.3.2.3. Social landscape
3.3.2.4. Technological landscape
3.3.2.5. Environmental landscape
3.3.2.6. Legal landscape
Chapter 4. China Lung Cancer Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Disease Type Segment Dashboard
4.2. China Lung Cancer Therapeutics Market: Disease Type Movement Analysis
4.3. China Lung Cancer Therapeutics Market by Disease Type Outlook (USD Million)
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. Non-small Cell Lung Cancer (NSCLC)
4.5.1. Non-small Cell Lung Cancer (NSCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Small Cell Lung Cancer (SCLC)
4.6.1. Small Cell Lung Cancer (SCLC) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. China Lung Cancer Therapeutics Market: Therapeutics Class Estimates & Trend Analysis
5.1. Therapeutics Class Segment Dashboard
5.2. China Lung Cancer Therapeutics Market: Therapeutics Class Movement Analysis
5.3. China Lung Cancer Therapeutics Market by Therapeutics Class Outlook (USD Million)
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Chemotherapy
5.5.1. Chemotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. Radiation Therapy
5.6.1. Radiation Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Immunotherapy
5.7.1. Immunotherapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.8. Targeted Therapy
5.8.1. Targeted Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.9. Other Treatments
5.9.1. Other Treatments Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Competitive Landscape
6.1. Market Participant Categorization
6.2. Key Company Profiles
6.2.1. AstraZeneca
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Roche
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Pfizer
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. Novartis
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Merck & Co.
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
6.2.6. Bristol-Myers Squibb
6.2.6.1. Company overview
6.2.6.2. Financial performance
6.2.6.3. Product benchmarking
6.2.6.4. Strategic initiatives
6.2.7. Eli Lilly and Company
6.2.7.1. Company overview
6.2.7.2. Financial performance
6.2.7.3. Product benchmarking
6.2.7.4. Strategic initiatives
6.2.8. Boehringer Ingelheim
6.2.8.1. Company overview
6.2.8.2. Financial performance
6.2.8.3. Product benchmarking
6.2.8.4. Strategic initiatives
6.2.9. Johnson & Johnson (Janssen Pharmaceuticals)
6.2.9.1. Company overview
6.2.9.2. Financial performance
6.2.9.3. Product benchmarking
6.2.9.4. Strategic initiatives
6.2.10. BeiGene
6.2.10.1. Company overview
6.2.10.2. Financial performance
6.2.10.3. Product benchmarking
6.2.10.4. Strategic initiatives
6.2.11. Innovent Biologics
6.2.11.1. Company overview
6.2.11.2. Financial performance
6.2.11.3. Product benchmarking
6.2.11.4. Strategic initiatives
6.2.12. Jiangsu Hengrui Medicine Co., Ltd.
6.2.12.1. Company overview
6.2.12.2. Financial performance
6.2.12.3. Product benchmarking
6.2.12.4. Strategic initiatives
6.2.13. China National Pharmaceutical Group (Sinopharm)
6.2.13.1. Company overview
6.2.13.2. Financial performance
6.2.13.3. Product benchmarking
6.2.13.4. Strategic initiatives
6.2.14. Shanghai Junshi Biosciences Co., Ltd.
6.2.14.1. Company overview
6.2.14.2. Financial performance
6.2.14.3. Product benchmarking
6.2.14.4. Strategic initiatives



List of Figures

List of Figures

Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 China lung cancer therapeutics market segmentation
Fig. 7 Market driver analysis (Current & future impact)
Fig. 8 Market restraint analysis (Current & future impact)
Fig. 9 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 10 Porter’s Five Forces Analysis
Fig. 11 China lung cancer therapeutics market, disease type outlook key takeaways (USD Million)
Fig. 12 China lung cancer therapeutics market: disease type movement analysis 2023 & 2030 (USD Million)
Fig. 13 Non-small cell lung cancer (NSCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 14 Small cell lung cancer (SCLC) market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 15 China lung cancer therapeutics market, therapeutic class outlook key takeaways (USD Million)
Fig. 16 China lung cancer therapeutics market: therapeutic class movement analysis 2023 & 2030 (USD Million)
Fig. 17 Chemotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 18 Radiation therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 19 Immunotherapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Targeted therapy market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Other treatments market revenue estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 China lung cancer therapeutics Market, end use outlook key takeaways (USD Million)

List of Tables

List of Tables

Table 1 List of Secondary Sources
Table 2 List of Abbreviations
Table 3 China lung cancer therapeutics market, by disease type, 2018 - 2030 (USD Million)
Table 4 China lung cancer therapeutics market, by therapeutic class, 2018 - 2030 (USD Million)